The T2DM patient with kidney disease – What is going wrong? How can we do better
One in three T2DM patients will develop kidney disease over their lifetime. Clinicians need to be alert to the possible early presence of kidney disease in their patients and ensure that therapy is selected with lowest possible hypoglycaemic risk
Learning objectives
- To understand the importance of preventing advancement in renal disease in patients with T2DM as currently 20-40% of these patients will develop Diabetic Kidney Disease
- As Diabetic Kidney Disease (DKD) carries a higher risk of hypoglycaemia, it is important to select glucose-lowering agents with a low risk causing patients second-generation analogue basal insulins should be a favoured option for patients with DKD
To access this module, please register or login: